EFG Asset Management North America Corp. Decreases Stock Position in Zoetis Inc. $ZTS

Key Points

• EFG Asset Management North America Corp. reduced its stake in Zoetis Inc. by 23.8%, now owning 12,878 shares valued at approximately $2.12 million.
• Several institutional investors, including Vanguard Group Inc. and Polen Capital Management LLC, have increased their stakes in Zoetis during the same period, indicating continued institutional interest.
• Zoetis reported earnings of $1.76 per share for the last quarter, exceeding analysts' estimates, with total revenue reaching $2.46 billion.

EFG Asset Management North America Corp. lessened its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 23.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 12,878 shares of the company's stock after selling 4,023 shares during the period. EFG Asset Management North America Corp.'s holdings in Zoetis were worth $2,120,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. 1248 Management LLC acquired a new position in shares of Zoetis in the 1st quarter valued at about $27,000. Saudi Central Bank acquired a new position in shares of Zoetis in the 1st quarter valued at about $29,000. Cornerstone Planning Group LLC lifted its stake in shares of Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after purchasing an additional 88 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its stake in shares of Zoetis by 87.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after purchasing an additional 120 shares during the period. Finally, Sound Income Strategies LLC lifted its stake in shares of Zoetis by 141.4% in the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after purchasing an additional 164 shares during the period. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Performance

Shares of ZTS traded down $1.44 on Monday, reaching $151.88. 3,312,971 shares of the company's stock traded hands, compared to its average volume of 2,296,223. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a market cap of $67.31 billion, a PE ratio of 26.14, a PEG ratio of 2.46 and a beta of 0.88. The stock's 50 day simple moving average is $153.16 and its two-hundred day simple moving average is $157.73. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis's revenue was up 4.2% on a year-over-year basis. During the same period last year, the business posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of recent analyst reports. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Piper Sandler upped their price target on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Zoetis currently has a consensus rating of "Moderate Buy" and an average price target of $202.43.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.